Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Morath

Showing results (191-200 of 198) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 198 results.
Transplantation Direct|August 12, 2024
Risk Stratification Before Living Donor Kidney Transplantation in Patients With Preformed Donor-specific Antibodies by Different Crossmatch MethodsMalte Ziemann, Monika Lindemann, Michael Hallensleben, et al.
The Journal of Clinical Investigation|January 29, 2020
Phase I trial of donor-derived modified immune cell infusion in kidney transplantationChristian Morath, Anita Schmitt, Christian Kleist, et al.
Journal of the American Society of Nephrology : JASN|September 22, 2022
Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant RecipientsChristian Morath, Matthias Schaier, Eman Ibrahim, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 28, 2020
Should kidney allografts from old donors be allocated only to old recipients?Caner Süsal, Gizem Kumru, Bernd Döhler, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|June 25, 2026
Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus reportStefan Reuter, Louise Benning, Andrea Dick, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 25, 2016
High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre surveyVolker Assfalg, Norbert Hüser, Marieke van Meel, et al.
Pageof 20

Showing results (191-200 of 198) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 198 results.
Transplantation Direct|August 12, 2024
Risk Stratification Before Living Donor Kidney Transplantation in Patients With Preformed Donor-specific Antibodies by Different Crossmatch MethodsMalte Ziemann, Monika Lindemann, Michael Hallensleben, et al.
The Journal of Clinical Investigation|January 29, 2020
Phase I trial of donor-derived modified immune cell infusion in kidney transplantationChristian Morath, Anita Schmitt, Christian Kleist, et al.
Journal of the American Society of Nephrology : JASN|September 22, 2022
Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant RecipientsChristian Morath, Matthias Schaier, Eman Ibrahim, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|April 28, 2020
Should kidney allografts from old donors be allocated only to old recipients?Caner Süsal, Gizem Kumru, Bernd Döhler, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|June 25, 2026
Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus reportStefan Reuter, Louise Benning, Andrea Dick, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 25, 2016
High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre surveyVolker Assfalg, Norbert Hüser, Marieke van Meel, et al.
Pageof 20